Last update 23 Jan 2025
Cell Lab Med

Cell Lab Med

Startups
|
Private Company|
2019|
Seoul, South Korea
|
10-50
|
www.cellabmed.com

Overview

Tags

Neoplasms
Nervous System Diseases
Endocrinology and Metabolic Disease
CAR-T
Monoclonal antibody
Universal CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms6
Endocrinology and Metabolic Disease1
Nervous System Diseases1
Top 5 Drug TypeCount
CAR-T4
Monoclonal antibody1
Universal CAR-T1
Top 5 TargetCount
IL-13Rα2(Interleukin-13 receptor subunit alpha-2)1
HGF(Hepatocyte growth factor)1

Related

7
Drugs associated with Cell Lab Med
Umikibart
Target
HGF
Mechanism
HGF inhibitors
Active Org.
Cell Lab MedCell Lab MedStartup
Originator Org.
Yooyoung Pharm Co. Ltd.Yooyoung Pharm Co. Ltd.
Active Indication
Colorectal Cancer [+2]
Inactive Indication
Advanced Malignant Solid Neoplasm [+2]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
YYB-103
Target
IL-13Rα2
Mechanism
IL-13Rα2 inhibitors [+2]
Active Org.
Cell Lab MedCell Lab MedStartup
Originator Org.
Yooyoung Pharm Co. Ltd.Yooyoung Pharm Co. Ltd.
Active Indication
Glioblastoma Multiforme
Inactive Indication
Amyotrophic Lateral Sclerosis [+1]
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
CLM-105
Target-
Mechanism-
Active Org.
Cell Lab MedCell Lab MedStartup
Originator Org.
Cell Lab MedCell Lab MedStartup
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Cell Lab Med
NCT05540873
/ Unknown statusPhase 1
A Single-center, Single-arm, Open-label Phase 1 Clinical Trial to Assess the Safety and Tolerability of YYB-103, IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell (CAR-T) in Treating Patients With Refractory or Recurrent Malignant Glioma
NCT04368507
/ CompletedPhase 1/2
A Phase 1b/2a Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab) in Combination With Irinotecan in Metastatic or Recurrent Colorectal Cancer Patients
NCT02499224
/ CompletedPhase 1
A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab), in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
100 Clinical Results associated with Cell Lab Med
Login to view more data
0 Patents (Medical) associated with Cell Lab Med
Login to view more data
100 Deals associated with Cell Lab Med
Login to view more data
100 Translational Medicine associated with Cell Lab Med
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
4
1
Phase 1 Clinical
Phase 2 Clinical
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Umikibart
 ( HGF )		Colorectal Cancer
More
Phase 2
YYB-103
 ( IL-13Rα2 )		Glioblastoma Multiforme
More
Phase 1
CLM-201
Solid tumor
More
Discovery
CLM-104
Solid tumor
More
Discovery
CLM-202
Solid tumor
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free